Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: Structural and individual-level changes, 1996 versus 2003

American Journal of Public Health

Volumn 96, Issue 8, 2006, Pages 1347-1353

  Deibert, Ryan J ^e   Goldbaum, Gary ^a,b   Parker, Theodore R ^b   Hagan, Holly ^c   Marks, Robert ^d   Hanrahan, Michael ^d   Thiede, Hanne ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Public Health Seattle King County ^*

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^d Public Health Seattle King County   (United States)

^e OREGON DEPARTMENT OF HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE POLICY; HUMAN; INTRAVENOUS DRUG ABUSE; LAW; NORMAL HUMAN; OUTCOME ASSESSMENT; PHARMACIST; PHARMACIST ATTITUDE; PHARMACY; PROFESSIONAL PRACTICE; PURCHASING; REVIEW; SYRINGE; TELEPHONE; UNITED STATES; ARTICLE; CLINICAL PRACTICE; COMMUNICABLE DISEASE; COUNSELING; CROSS-SECTIONAL STUDY; EVALUATION; HEALTH PERSONNEL ATTITUDE; INSTRUMENT STERILIZATION; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; POLICY; PREVENTIVE HEALTH SERVICE; PSYCHOLOGICAL ASPECT; STATISTICS; SUBSTANCE ABUSE; TEACHING; WASTE DISPOSAL;

ATTITUDE OF HEALTH PERSONNEL; COMMUNITY-ACQUIRED INFECTIONS; COUNSELING; CROSS-SECTIONAL STUDIES; HEALTH POLICY; HUMANS; MEDICAL WASTE DISPOSAL; NEEDLE-EXCHANGE PROGRAMS; ORGANIZATIONAL POLICY; PATIENT SIMULATION; PHARMACIES; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; STERILIZATION; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES; WASHINGTON;

EID: 33746704527     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2003.032698     Document Type: Review

References (42)

1. Lee LM, Mckenna M, Sharpe TT. HIV diagnoses among injection-drug users in states with HIV surveillance: 25 states, 1994-2000. MMWR. 2003; 52:634-636.
2. Centers for Disease Control and Prevention. National Hepatitis C Prevention Strategy: A Comprehensive Strategy for the Prevention and Control of Hepatitis C Virus Infection and its Consequences. Summer 2001. Available at: http://www. cdc.gov/ncidod/diseases/hepatitis/c/plan/index.htm. Accessed July 18, 2004.
3. Van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433-437.
4. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
5. Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19:247-252.
6. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369-382.
7. Gleghora AA, Wright-De Aguero L, Flynn C. Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven US metropolitan cities. J Acquir Immune Defic Syndr. 1998;(suppl 1):18:S30-S36.
8. Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;(Suppl 1):18:S37-S44.
9. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998; 113(suppl 1):75-80.
10. Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among participants in the Tacoma syringe exchange. Am J Public Health. 1995;85:1531-1537.
11. Guydish J, Bucardo J, Young M, Woods W, Grinstead O, Clark W. Evaluating needle exchange: are there negative effects? AIDS. 1993;7:871-876.
12. Hagan H, Des Jarlais DC, Purchase D, Friedman SR, Reid T, Bell TA. An interview study of participants in the Tacoma syringe exchange. Addiction. 1993;88:1691-1697.
13. Paone D, Des Jarlais DC, Caloir S, Friedmann P, Ness I. New York City syringe exchange: an overview. In: Proceedings of the Workshop on Needle Exchange and Bleach Distribution. Washington, DC: National Academy Press; 1994.
14. Sheridan J, Strang J, Barber N, Glanz A. Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales. BMJ. 1996;313:272-274.
15. Young K. Fitpacks Evaluation Study. Sydney, Australia: AIDS Bureau, New South Wales Health Department; March 1992.
16. Lungley S, Baker M. The Needle and Syringe Exchange Scheme in Operation. Wellington, New Zealand: New Zealand Department of Health; 1990.
17. Ingold FR, Ingold S. The effects of the liberalization of syringe sales on the behavior of intravenous drug users in France. Bull Narc. 1989;41:67-81.
18. Jones TS, Coffin PO. Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Am Pharm Assoc. 2002;42(suppl 2):S6-S9.
19. Burns S, Vernick JS, Ditzler A, Strathdee S. The legality of selling or giving syringes to injection drug users. J Am Pharm Assoc. 2002;42(suppl 2)513-518.
20. Gostin LO, Lazzarini Z, Flaherty K, Jones TS. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. JAMA. 1997;277:53-62.
21. Ettelson R. Sell needles and syringes to IV drug abusers? Pharm Times 1991;57:107-114.
22. Compton WM III, Cottler LB, Decker SH, Mager D, Stringfellow R. Legal needle buying in St. Louis. Am J Public Health. 1992;82:595-596.
23. Glantz A, Byrne C, Jackson P. Role of community pharmacies in prevention of AIDS among injecting drug misusers: findings of a survey in England and Wales. BMJ. 1989;299:1076-1079.
24. Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc. 2002;42(suppl 2):S40-S45.
25. Lewis BA, Koester SK, Bush TW. Pharmacists' attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc. 2002;42(suppl 2)546-551.
26. Reich W, Compton WM, Horton JC, et al. Pharmacist ambivalence about sale of syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S52-S57.
27. Rich JD, Martin EG, Macalino GE, Paul RV, McNamara S, Taylor LE. Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2)558-561.
28. Hopkins SG, Fancy K, eds. HIV/AIDS Epidemiology Profile for Community Planning. Seattle, Wash: Public Health-Seattle & King County; 2001.
29. Williams DH. Increasing legal and regulatory support for pharmacy syringe sales to injection drug users, Washington State, 1999-2002. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S23-S24.
30. Marks RW, Hanrahan M, Williams DH, Goldbaum G, Thiede H, Wood RW. Encouraging pharmacy sale and safe disposal of syringes in Seattle, Washington. J Am Pharm Assoc (Wash). 2002; 42(6 suppl 2):S26-S27.
31. Washington State Board of Pharmacy, Washington State Pharmacy Association, Public Health-Seattle and King County. HIV and Hepatitis Prevention: Access to Sterile Syringes [joint letter to Washington State pharmacists]. July, 2002; Available at: http://www. cdc.gov/idu/pubs/ Joint%20letter%207-17-02.pdf. Accessed April 19, 2006.
32. Parker TR. Attitudes of Pharmacists Towards Intravenous Drug Use and Increased Needle/Syringe Availability: How Available Are "Works" in Seattle! [master's thesis]. Seattle, WA: University of Washington; 1996.
33. Wright-de Aguero L, Weinstein B, Jones TS, Miles J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practice. J Acquir Immune Defic Syndr. 1998;(suppl 1):18:S102-S110.
34. Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers-Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:82-89.
35. Finklestein R, Tiger R, Greenwald R, Mukherjee R. Pharmacy syringe sale practice during the first year of expanded syringe availability in New York City (2001-2002). J Am Pharm Assoc. 2002;42(6 suppl 2):S83-S87.
36. Compton WM, Horton JC, Cottler LB, Booth R, Leukefeld CG, Singer M, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004;81:661-670.
37. The Twin Epidemics of Substance Use and HIV. Washington, DC: National Commission on Acquired Immune Deficiency Syndrome; 1991.
38. Lurie P, Reingold A. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Berkeley, CA: University of California, School of Public Health; 1993.
39. Normand J, Vlahov D, Moses LE, eds. Preventing HIV Transmission: the Role of Sterile Needles and Bleach. Washington, DC: National Academy of Sciences; 1995.
40. The Effectiveness of AIDS Prevention Efforts. Washington, DC: US Office of Technology Assessment; 1995.
41. National Alliance of State and Territorial AIDS Directors. HIV Prevention & Access to Sterile Syringes [joint letter issued by the American Medical Association, American Pharmaceutical Association, Association of State and Territorial Health Officials, National Association of Boards of Pharmacy, National Alliance of State and Territorial AIDS Directors]. October 1999. Available at: http://www. cdc.gov/idu/pubs/hiv_prev_acc.htm. Accessed July 18, 2004.
42. Jones TS, Vlahov D. Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;(suppl 1):18:S1-S5.